251 related articles for article (PubMed ID: 19209130)
1. Therapeutic strategy of papillary microcarcinoma of the thyroid gland: a nuclear medicine perspective.
Riemann B; Schober O
Minerva Endocrinol; 2009 Mar; 34(1):81-7. PubMed ID: 19209130
[TBL] [Abstract][Full Text] [Related]
2. Radioactive iodine ablation does not prevent recurrences in patients with papillary thyroid microcarcinoma.
Kim HJ; Kim NK; Choi JH; Kim SW; Jin SM; Suh S; Bae JC; Min YK; Chung JH; Kim SW
Clin Endocrinol (Oxf); 2013 Apr; 78(4):614-20. PubMed ID: 22957654
[TBL] [Abstract][Full Text] [Related]
3. The effects of surgery, radioiodine, and external radiation therapy on the clinical outcome of patients with differentiated thyroid carcinoma.
Tsang RW; Brierley JD; Simpson WJ; Panzarella T; Gospodarowicz MK; Sutcliffe SB
Cancer; 1998 Jan; 82(2):375-88. PubMed ID: 9445196
[TBL] [Abstract][Full Text] [Related]
4. Treatment for microcarcinoma of the thyroid--clinical experience.
Küçük NO; Tari P; Tokmak E; Aras G
Clin Nucl Med; 2007 Apr; 32(4):279-81. PubMed ID: 17413573
[TBL] [Abstract][Full Text] [Related]
5. [Diffuse sclerosing variant of papillary thyroid carcinoma].
Manrique Franco K; Domínguez Fernández R; Lara Capellán JI; Renedo Pascual G; Rovira Loscos A
Endocrinol Nutr; 2010 Dec; 57(10):500-2. PubMed ID: 20843752
[No Abstract] [Full Text] [Related]
6. [Analysis of the factors affecting the efficacy of (131)I remnant ablation in patients after thyroidectomy for papillary thyroid microcarcinoma].
Du F; Hu S; Wu C; Cheng Y; Wu LX; Liu JZ; Wu ZF; Li SJ
Zhonghua Zhong Liu Za Zhi; 2018 Aug; 40(8):610-613. PubMed ID: 30139032
[No Abstract] [Full Text] [Related]
7. Follow-up of differentiated thyroid cancer.
Pacini F
Eur J Nucl Med Mol Imaging; 2002 Aug; 29 Suppl 2():S492-6. PubMed ID: 12192551
[TBL] [Abstract][Full Text] [Related]
8. Aggressiveness and outcome of papillary thyroid carcinoma (PTC) versus microcarcinoma (PMC): a mono-institutional experience.
Cappelli C; Castellano M; Braga M; Gandossi E; Pirola I; De Martino E; Agosti B; Rosei EA
J Surg Oncol; 2007 Jun; 95(7):555-60. PubMed ID: 17226813
[TBL] [Abstract][Full Text] [Related]
9. Cancer recurrence in papillary thyroid microcarcinoma: a multivariate analysis on 231 patients with a 12-year follow-up.
Pedrazzini L; Baroli A; Marzoli L; Guglielmi R; Papini E
Minerva Endocrinol; 2013 Sep; 38(3):269-79. PubMed ID: 24126547
[TBL] [Abstract][Full Text] [Related]
10. Radioiodine therapy for papillary and follicular thyroid carcinoma.
Klain M; Ricard M; Leboulleux S; Baudin E; Schlumberger M
Eur J Nucl Med Mol Imaging; 2002 Aug; 29 Suppl 2():S479-85. PubMed ID: 12192549
[TBL] [Abstract][Full Text] [Related]
11. [Treatment with (131)I of thyroid remnants in a patient with papillary thyroid carcinoma and end-stage chronic renal failure].
Andres A; Tardín L; Santapau A; Razola P; Prats E; Parra A; Rivas MA; Ruiz P; Alvarez R; Camara A; Banzo J
Rev Esp Med Nucl; 2010; 29(1):32-5. PubMed ID: 20018412
[TBL] [Abstract][Full Text] [Related]
12. Thyroid remnant ablation in patients with papillary cancer: a comparison of low, moderate, and high activities of radioiodine.
Kusacic Kuna S; Samardzic T; Tesic V; Medvedec M; Kuna K; Bracic I; Despot M; Dodig D
Nucl Med Commun; 2009 Apr; 30(4):263-9. PubMed ID: 19247212
[TBL] [Abstract][Full Text] [Related]
13. Follow-up and management of differentiated thyroid carcinoma: a European perspective in clinical practice.
Schlumberger M; Pacini F; Wiersinga WM; Toft A; Smit JW; Sanchez Franco F; Lind P; Limbert E; Jarzab B; Jamar F; Duntas L; Cohen O; Berg G
Eur J Endocrinol; 2004 Nov; 151(5):539-48. PubMed ID: 15538930
[TBL] [Abstract][Full Text] [Related]
14. Esophageal diverticulum presenting as metastatic thyroid mass on iodine-131 scintigraphy.
Rashid K; Johns W; Chasse K; Walker M; Gupta SM
Clin Nucl Med; 2006 Jul; 31(7):405-8. PubMed ID: 16785810
[No Abstract] [Full Text] [Related]
15. [Differentiated thyroid cancers].
Gorgone S; Campennì A; Calbo E; Catalfamo A; Sciglitano P; Sofia L; Niceta M; Borzì R; Calbo L
G Chir; 2009; 30(1-2):26-9. PubMed ID: 19272228
[TBL] [Abstract][Full Text] [Related]
16. Management of coexisting thyrotropin/growth-hormone-secreting pituitary adenoma and papillary thyroid carcinoma: a therapeutic challenge.
Nguyen HD; Galitz MS; Mai VQ; Clyde PW; Glister BC; Shakir MK
Thyroid; 2010 Jan; 20(1):99-103. PubMed ID: 20067380
[TBL] [Abstract][Full Text] [Related]
17. Clinical experience with recombinant human thyrotrophin (rhTSH) in the management of patients with differentiated thyroid cancer.
Mariani G; Ferdeghini M; Augeri C; Villa G; Taddei GZ; Scopinaro G; Boni G; Bodei L; Rabitti C; Molinari E; Bianchi R
Cancer Biother Radiopharm; 2000 Apr; 15(2):211-7. PubMed ID: 10803328
[TBL] [Abstract][Full Text] [Related]
18. [Should thyroxine treatment be discontinued for four weeks before I(131) thyroid ablation?].
Luna R; Penín M; Seoane I; Alvarez E; Palmeiro R; García-Mayor R
Endocrinol Nutr; 2012 Apr; 59(4):227-31. PubMed ID: 22436880
[TBL] [Abstract][Full Text] [Related]
19. [Treatment for microcarcinoma of the thyroid. Clinical experience].
Conzo G; Esposito MG; Di Marzo M; Astarita G; Celsi S
Tumori; 2003; 89(4 Suppl):210-1. PubMed ID: 12903596
[TBL] [Abstract][Full Text] [Related]
20. [Radioiodine in the treatment of generalized papillary and follicular thyroid carcinoma].
Mäenpää H
Duodecim; 2014; 130(6):573-9. PubMed ID: 24724456
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
